Reddit Posts
Bullish News for Psychadelic Stocks? "FDA Issues First Draft Guidance on Clinical Trials with Psychedelic Drugs..."
Special Situations for Thursday: $DSS, $ATAI, $MIGI, $BIOL
Special Situations for Thursday: $DSS, $ATAI, $MIGI, $BIOL
Atai stock rises amid restructuring with ~30% job cuts (NASDAQ:ATAI)
Mexican Senator To File Psychedelics Legalization Bill, With U.S. Congressman Backing International Reform Push
What's your opinion on ATAI and other psychedelic medicine companies?
Unlock The Mind - Solving America's Mental Health Crisis with $ATAI (Atai Life Sciences). Full DD on the Psychedelic sector potential. 🍄
Unlock The Mind - Solving America's Mental Health Crisis with $ATAI (Atai Life Sciences) Full DD on the Psychedelic sector potential. 🍄 DD
A Look at "R-Ketamine" Drug Development Ahead of $ATAI's PCN-101 Phase 2a December 2022 Data Readout (Psychedelic Stock)
ATAI Life Sciences what do you guys think?
What is your opinion on small cap biotech stocks like TSHA and ATAI?
ATAI, A Company with a lot of potential for short term and long-term gains.
What’s your favorite Magic Mushroom Penny Stock? A few I’ve been looking into are FTRP, SEEL, CYBN, CMPS, GHRS, ATAI, MNMD.
Cathie Wood makes her first investment in Psychedelics
$IGXT Due Diligence - Not your average biotech play. Dissolvable Oral films with medicine on them, faster onset, compliance, skip first pass digestion (similar to injections).
The Upcoming Psychedelic Sector Opportunity 🍄 (FDA Phase 2b data readout in November 2021)
The Upcoming Psychedelics Sector #ShroomBoom 🍄 (November 2021 FDA Phase 2b Catalyst)
$IGXT Up 43% in the last four trading sessions despite heavy short volume
Update On $IGXT since my last post, up about 41% since.
$IGXT Patient Screening to Resume in IntelGenx’s ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease.
$IGXT; Pennystock that has turned the corner and gone from R&D to Manufacturing. Oral film Delivery system (Oral films that go directly to bloodstream, Skip first pass digestion). The market hasn't caught onto this company yet..
IntelGenx Receives U.S.$6 Million in Additional Loans from atai Life Sciences and Conditional Approval to Graduate to Toronto Stock Exchange!!!
$ATAI psychedelics getting ready to go apeshit.
IntelgenX officially launches Rizaport in spain!!
Mentions
Throw some on 2027 ATAI calls. Was planning to do the same, and seems like good time to with it being down last few days. Good luck
Anyone know what is happening with ATAI?
ATAI ..thiel is heavily invested , rfk hates ssris ….NIH gave them a multi year grant …so many catalysts
ATAI. Psychedelic medicine is gaining steam and this is the best of the breed. Fast acting, safe and effective therapies are going to go mainstream in the next 5-10 years. Big pharma has only begun to catch on (see J&J's Spravato blockbuster ketamine therapy). Love them or hate them, the current administration is fast-tracking this stuff. Philosophically a very anti-AI investment, but that only boosts my conviction.
gotta yank my $$$ (except ATAI) out to do a house payment. see you guys in 6 months when I can "save" again.
You kidding me?! $MNMD and $ATAI...
I recommend ATAI a few times last week. Up 17% today (plus 6% more after market). You’re welcome.
Whoever downvoted me earlier when I said buy ATAI after they got FDA approved DMT, I hope the wheels on your car fall off
ATAI saved me from POET loss
PCSA PRSO ADAP DVLT CAN ATAI .. all have had some green during these blood bath days. Means ppl have some conviction despite fear
DMT got FDA approval, buy up some ATAI if you’ve met any deemster jesters 🔥
The AH movement on $ATAI is more insane than my EX GF LOLZ
Hell yea, ATAI is below 5$ again!
I think of you every day when I check my investment account and see it up by another $25k. +$600k and counting between ATAI and CMPS
ATAI - Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside. Psychedelic treatments! UP over 15% today.
ATAI - Up about 10% today and continues to rise. PT at $12, staying long, bought in at 3.08.
ATAI is saving my portfolio today
BPL-003 has a similar structure and effects as psilocybin and was granted a breakthrough therapy designation (BTD) back in 10/2018. There's a strong possibility that ATAI gets the BTD for BPL-003. BTD's are most likely to occur after completion of phase 2, and ATAI's BPL-003 ended in July 2025. According to corporate updates from ATAI Life Sciences, the company planned to hold an End-of-Phase 2 (EOP2) meeting with the FDA to discuss the BPL-003 program in the third quarter of 2025. As of early October 2025, no official outcome from this meeting has been announced publicly. Key context on the meeting: * **Purpose:** The meeting was to discuss the path forward for Phase 3 trials for BPL-003, a therapy for treatment-resistant depression (TRD). * **Timing:** The meeting was scheduled for the second half of 2025, after atai and Beckley Psytech announced positive Phase 2a and 2b data for BPL-003. * **Potential outcome:** Analysts and investors have discussed the possibility that atai could receive Breakthrough Therapy Designation (BTD) during this time, which would expedite the development process.
This Reddit post is one of the most accurate and well-balanced warnings I’ve seen about small-cap pharma investing — and it aligns with my firsthand experience. That said, it’s also worth noting how fascinating this sector has been over the past six months. The **biotech indices have more than doubled the S&P 500’s last 6 months returns** and even outperformed tech ETFs at times — and the sector just had its **best week in years.** I'm tracking and benefiting from real momentum in areas like **gene therapy**, **RNA therapeutics**, and even some **psychedelic-related neuroscience** plays. Plus many exciting one-product in-development companies are there to be found - if you know the business (few people do). A lot of companies that were absolutely crushed last year and very undervalued at the start of this year have been quietly recovering from the floor — some example names like *Ionis, Arrowhead, Nektar, ATAI, UniQure* have all had solid runs recently, some of course due to new Clinical Trial results (this is NOT a recommendation to buy in now given the price rises these saw - just examples) Of course, there are always the “one great drug” hopefuls and takeover dreams floating around — that’s part of the ecosystem. But what makes biotech so different from “normal” investing is just how unpredictable it is. Even when you know the science, the market reaction can appear irrational if you do not know the bigger picture/dynamics that will not obvious to most retail investors. For me, the safest (and most enjoyable) approach is a **portfolio mindset** — not betting too much on single miracles, but following themes, a bit like Big Pharma does with its pipelines. It’s risky, but fascinating — part science, part psychology. PS I'm ex-Pharma/Biotech and I invest entirely in Biotech - as it's the sector I know, even still - I keep most my initial biotech penny stocks to 1-2% of my portfollio
I keep dipping in and out of ATAI. It's alright, but there are better psilocybin plays out there.
No one talking about ATAI OR BCTX?
HOP on the ATAI train - Theil's next pump
Psychedelic Sector (Right Sector) - MNMD & ATAI (Right Stocks), Most all others wrong stocks in that sector.
ATAI all the way for me.Till deliberation day.
Sold some ATAI for EONR.
ATAI, CURA, PESO, PHIO. Original plays are still being called out. They're just drowning in noise.
IXHL goes down as the day's sole loss. DFLI, NUAI, PHGE, ATAI, and FEIM all performed admirably.
Sold Cap-XX (8% gain) to re-enter ATAI Life Sciences.
Eyeing ATAI Life Sciences. Thiel's backing plus Trump admin support for psychedelics are a powerful duo.
ATAI Life Sciences. US authorities have made positive signals about psychedelics.
In light of all the mental illness-induced violence in this country over the past months, weeks, days, and decade or two... I've been slowly but surely and small-time investing in depression/schizo pharma-shroom stocks and whatnot. Nothing too serious but, I've got sizable stakes in IXHL and ATAI and RVPH.
ATAI just got $11M from the federal gov. Up 300% this year without a drug even on the market yet. Def going to 10x in the next two years. Don't miss out 🍄 https://preview.redd.it/63p2cwpfu3rf1.jpeg?width=1080&format=pjpg&auto=webp&s=76cb96918716018b7979ccbe182122174e8cef25
I'm wondering when BTAI is going to start heading up again, it's gone down a lot from its peak. Don't have anything in it now, but keeping an eye on it since $5 may be possible again if it reverses. Was watching ATAI as well, but missed the pump on it this week. Anyone still feeling optimistic about BTAI?
I would have told you ATAI but it popped off today, might not be a great time to buy, but the price target is still to 2x this year.
ATAI back to 5 then loading up on May leaps
ATAI making groundbreaking advances on depression drug that could alter the market entirely
There's ATAI, theres NRXP, theres many more. I believe in those treatments, but hell, I got burned by many of those.
ATAI 52 week high 🍄 https://preview.redd.it/kgdoogcwixqf1.jpeg?width=1080&format=pjpg&auto=webp&s=19f2be6955c5e2642bce331767efbe49c7023755
ATAI still climbing, good phase 2 drug results released today. It's not too late ... https://preview.redd.it/q0lylyk68xqf1.jpeg?width=1080&format=pjpg&auto=webp&s=13e4d3d5a843bbc60ce7e1934d15b671af748296
ATAI gets positive research results 🚀
ATAI and MNMD have done pretty well YTD. I started that play perfectly last November, but then paper handed both of them during the tariff fiasco in the spring.
I tried to tell yall about ATAI 🤷♂️ https://preview.redd.it/pyutjfcrtqqf1.jpeg?width=1080&format=pjpg&auto=webp&s=b7bf3291bf7b17159885a3ff61952f29a2da24f6
number 1 was SOFI. i first bought around $20, sold when it was around $27 (i think pre-market), and bought back in when it went to $18, thinking i could ride it back up again. i was new to the markets like a lot of people and i really didn't know what i was doing, but as i got to know the company i started to really get "invested" in them. i held over a dozen different stocks, but SOFI earned my highest conviction. i also held onto a few hundred PLTR stocks, but i didn't do more because the classified nature of the majority of their work and technology made it feel like i was just gambling, and when tech really started to fall i wanted to make only intelligent moves that i could justify with the data. i'm still holding 9,000 shares of SOFI at a cost basis of $7.50/share. i'm also holding 15,000 shares of ATAI @ $1.18/share. i had more, but i sold 8,000 shares in order to take advantage of the healthcare sector. and i sold all of my PLTR shares for the same reason. PLTR was up over 1,200%, so to ask for more than that just seemed ridiculous. i think the healthcare stocks will double before PLTR doubles again. so here we are.
Where do we see $ATAI heading?
is ATAI even penny anymore, seems like it's got good momentum and consolidated the mid 4s
I also like ATAI and ONDS. If you have patience and depending on their phase 3 trials CGTX has potential in the next couple years.
The volume on psychedelic stocks is crazy. PSIL ATAI CMPS CYBN are bout to blow
Psychedelic approvals must be coming with this volume ATAI PSIL CMPS CYBN
What's the long term price target of $ATAI? Also, seen 3-5 billion market cap number floated around, but that seems conservative.
I sold 40k shares of ATAI at 1.51 in april. It happens. And the more you look around and the more you buy/sell, the more frequently it happens. And I was happy when I sold since I bought at 1.38 and made 10% in a couple days
Don’t sleep on shroom stocks with all the data coming and the work with RFK’s FDA. CMPS and ATAI lead the pack.
$ATAI to the moon bby.
Continuing to buy psychedelic stocks, per usual. PSIL ATAI CYBN CMPS
Psychedelics approval is all but guaranteed with this administration and you’re going to miss the boat ATAI CYBN CMPS PSIL
Shroom stocks beating the odds today ATAI CYBN CMPS
Fair point but if it had drugs that weren't in the research phase, we wouldn't be talking about this on a penny stocks subreddit - To diversify that risk somewhat, ATAI does have quite a few treatments in their development pipeline (https://atai.com/programs-and-research/pipeline/) As far as policy risk, there have been a lot of statements by the current US administration that signal enthusiasm for psychedelic treatments - I linked a couple in my original post. I think it's likely that psychedelic treatments will face an added level of skepticism due to the history of psychedelics, but I believe there's a political, societal, and medical openness to psychedelic treatments that makes such stringent policy as outlawing psychedelic derived pharmaceuticals unlikely. Maybe if there were significant adverse events during testing, but another highlight of ATAI's BPL-003 phase 2 results is that they reported no serious adverse events - https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-announce-positive-topline.
I am sorry to say this, but since this is a stock market post. I was always told there are ways to make money during the world falling apart. I live in Appalachia, you know, where this type of shit affects a lot of these folks. Farmers, workers, small ag business, repair shops, etc. You can short DE and go long on ATAI and MNMD. I say this because the mental health of families is falling horribly in these areas. I have been seeing billboards for JNJ's Spravato in our area and that is a 1.7B blockbuster drug for which those other two I mentioned are going after. I will tell you this these is a need for new mental health treatments due to this shit. The ripple effect is crazy.
Trimming REITs (office space is already empty and a recession (caused by Ai and national and geopolitical turmoil) will drive more traditional companies with office space into bankruptcy and cause them to default on their lease -- I hope I'm wrong). Long term holdings (not adding) MNMD, ATAI, CMPS and a small one CMND. New-to-me long term holdings that I intend to add more off LLY, NVO, TSLA, CRCL, APP, PANW, FTNT).
Long-term, I focus on next-gen tech. Currently holding BiomX (bacteriophages), Intensity Therapeutics (T-cell immuno-oncology), ATAI Life Sciences (experimental mental health treatments), Solid Power (solid-state lithium batteries), Microbot Medical (surgical robots), and Hydrograph (fancypants graphene). I'm also closely eyeing CAP-XX (supercapacitors). There's some decent rare earth plays in pennyland, but most - except for UURAF and UAMY - are still in the explorer stage.
Good luck to the blsh players. Not gonna take a risk on it but if there is one thing I know it’s that Peter Theil is like Jon Jones and you don’t bet against him. ATAI should in no way be at $4 a share without even a phase 3 but here we are, I’ll be watching and taking notes
My current picks are SDLP (solid-state batteries); PHGE (bacteriophages); FEIM (quantum timing); UURAF (proprietary rare earth mining tech); ARRNF (rare earth explorer - ultra-high risk); HDGRAF (pure graphene - expect short-term reversal); GOOG (major AI upside), ATAI (experimental mental health treatments), and NG (UK National Grid: large-cap green energy play).
IONQ, QBTS, RGTI, QUBT, and ATAI - 4 quantum computing and 1 psilocybin. Quantum is the wave of the future and psilocybin is promising for brain disorders and diseases.
BTAI profits funded positions in ATAI, SLDP, and HDGRAF. Avoiding or scalping hype stocks (e.g. NCNA, NVNI, PHGE, IXHL) saved a lot of money.
Today's long-term buys: SDLP (solid-state batteries), ATAI (psychedelics), FEIM (quantum timing), and HDGRAF (ultra-strong graphene). Very sceptical of HDGRAF's claims to make the only 'true' graphene, and of such a product's relevance to bulk use cases (e.g. fashion). But they'll probably end up specialised in the space and defence industries, which is exactly what I want.
ATAI has been on a rip recently and as I understand it - that is one stock that is heavily propped up by insiders and retail. Going to be interesting to see what happens with these rate cuts.
Sold PHGE for a small profit (<4%). Will watch to see what it does at open. Also bought ATAI with CURA profits. A long-term hold. Might write a DD on it.
We are still along ways away from any type of psychedelic research being accepted; probably now more than 5 years ago. I have not done a literature review in a few years, but MindMed did not peak my interest due to the compound they were investigating; I was hopeful on ATAI, but the exclusion criteria for receiving these therapeutics is vast, and likely a barrier to those who wish to seek it out. With that being said, I see a future in this space, but I'm not sure how profitable it will be.
To some degree yes. That's why I'm split ATAI and MNMD
also it seems ATAI is selling CMPS major product, COMP360.
ATAI lowered their stake I followed their lead. I'm not against CMPS. But since ATAI still owns a portion I'm diversified to a degree.
I'm in both ATAI and MindMed. If you look at the PSIL ETF. Those two companies are the top two holdings.
Because i am a retard, i will short ATAI and CMPS today
Not arguing - informing. $ATAI $MNMD The U.S. administration and FDA are warming up to psychedelics going mainstream for four key reasons: 1. FDA Draft Guidance: In June 2023, the FDA issued its first-ever draft guidance titled “Psychedelic Drugs: Considerations for Clinical Investigations.” This document acknowledges the unique challenges of studying substances like psilocybin, LSD, and MDMA, and provides structured advice on trial design, safety monitoring, data collection, abuse potential assessment, and compliance with DEA regulations for Schedule I substances. Its release signals FDA’s intent to create a regulatory framework—rather than continue in suppression. 2. New Leadership Driving Faster Review: Under Health Secretary Robert F. Kennedy Jr., the administration has declared a priority to approve psychedelic therapies within 12 months. FDA head Marty Makary has proposed speeding up reviews (possibly down to a month) and has signaled willingness to relax stringent trial standards in certain cases, recognizing the challenges of placebo control in psychedelic studies 3. Bipartisan Political Momentum: Republican veteran lawmakers—like Representatives Morgan Luttrell, Dan Crenshaw, and Jack Bergman—have publicly advocated for controlled psychedelic therapy, especially for PTSD, bringing broad GOP support to what was once a fringe issue 4. State-Level Breakthroughs as Pressure Drivers: States like New Mexico have enacted therapeutic psilocybin law (effective April 8, 2025), while Texas is investing $50 million in clinical trials for ibogaine—despite it being Schedule I—in hopes of positioning these therapies for eventual federal approval
This is exactly why I put money on MNMD and ATAI they are playing in a space where you need to synthetically create and clinically administer these drugs. Mushrooms are going to be a commodity like cannabis, LSD and DMT are on a whole other level. You're not legalizing that stuff - they will reschedule and develop drugs. MNMD did trials with Cleveland Clinic, that's seems good enough of a partner for me. ATAI founder is well connected and backed. One of those two will be bought out or partnered within 6-10 months.
Most of them are crap. ATAI, MNMD and CMPS will be the horses here. ATAI never went through its cycle. MNMD was shit until the new CEO took over, CMPS only because CYBN is a joke.
AAPL effed me, but meta puts might save me if tomorrow is a red day. But ATAI is killing it